BioCentury | Sep 4, 2020
Product Development

Rain to advance growing precision oncology pipeline with $63M series B

...– Poly(ADP-ribose) polymerase RAD52 – RAD52 homolog Danielle Golovin milademetan (DS-3032) Tarlox...
BioCentury | May 24, 2019
Product Development

Why quizartinib hiccup at ODAC shouldn’t derail Daiichi’s 2025 cancer drug goals

...EGP-1) NSCLC Ph I DS-1205 AXL receptor tyrosine kinase (AXL; UFO) inhibitor NSCLC Ph I DS-3032...
BioCentury | Oct 27, 2017
Company News

Daiichi and MD Anderson partner to develop AML candidates

...including combination studies and trials using biomarkers, of compounds in Daiichi's pipeline, including quizartinib (AC220), DS-3032...
...of FMS-like tyrosine kinase 3 (FLT3; CD135), is in Phase III testing to treat AML. DS-3032...
...Tokyo:4568), Tokyo, Japan University of Texas MD Anderson Cancer Center , Houston, Texas Business: Cancer Allison Johnson DS-3032 DS-3201b quizartinib Daiichi...
BioCentury | Dec 15, 2016
Product R&D

p53 and Ras: Back from the dead

...small molecule MDM2 inhibitors in Phase I testing include AMG 232 from Amgen Inc. and DS-3032...
Items per page:
1 - 4 of 4